News Room

Consistent and Robust Development of Core Businesses

(Hong Kong —— Feburary 26,2026) Human Health Holdings Limited (“Human Health” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1419), a leading private integrated healthcare service provider in Hong Kong, announces its consolidated interim results for the six months ended 31 December 2025 (the “Interim Period of FY2026”).

During the Interim Period of FY2026, the Group achieved consistent and robust financial and operational performance amid a changing macroeconomic backdrop, further consolidating its leadership position in Hong Kong's private medical market. Through disciplined execution across its core segments, enhanced operational efficiency via digital tools, and the successful integration of acquired project, all major segments of the Group recorded revenue growth.

Financial Performance
• Revenue Growth: The Group's revenue for the Interim Period of FY2026 was approximately HK$342.4 million, representing an increase of approximately HK$26.6 million or 8.4% as compared with that of the Interim Period of FY2025.
• Profit Growth: Profit attributable to owners of the Company for the Interim Period of FY2026 was approximately HK$18.3 million, representing an increase of approximately HK$1.5 million or 8.5% compared to approximately HK$16.8 million for the Interim Period of FY2025.
• Earnings Per Share: Basic earnings per share for the Interim Period of FY2026 amounted to approximately HK4.8 cents (Interim Period of FY2025: approximately HK 4.4 cents)

Business Segment Performance
1. General Practice Segment
Revenue was approximately HK$213.9 million, representing a year-on-year increase of 3.5%. This growth was primarily driven by an increase in patient visits.

Further enhanced service scalability, accessibility, and community health coverage by expanding the telemedicine coverage networks, and promoting preventive health initiatives such as weight management programmes and metabolic health screenings.

Maintained close collaboration with the Hong Kong Government, activelyparticipating in key public health initiatives including the Seasonal InfluenzaVaccination Scheme, Pneumococcal Vaccination Programme, Chronic Disease Co-care Programme (“CDCC”), and the Colorectal Cancer Screening Programme (“CRC”), strengthening its role in community primary healthcare.

2. Specialties Segment

• Revenue was approximately HK$81.7 million, representing a year-on-year increase of 0.5%.
• Ophthalmology services and eye care services under the POLYEYE brand held their position as a primary pillar within the specialties segment. The Group continued to expand its service scope, underpinning POLYEYE’s positioning as a comprehensive eye care platform.
• Strengthened collaboration between the general practice and specialties segments through the integrated clinic operating system and the medical concierge services, facilitating effective referrals and optimising resource utilisation.

3. Dental Segment

• Revenue was approximately HK$46.8 million, representing a substantial year-on-year increase of 67.5%. This growth was mainly attributable to an increase in patient visits and the successful acquisition of Monarch Dental Clinic Limited (“Monarch Dental”) in February 2025.
• Following the acquisition of Monarch Dental, the Group's dental network expanded notably and fortified its service capacity. During the Interim Period of FY2026 ,the Group focused on operational alignment, practitioner engagement, and digital integration to lay the foundation for long-term synergies.

Integrated Services at Healthy Square H2
Healthy Square H2, the integrated health hub in Star House at Tsim Sha Tsui, continued to serve as a key integrated healthcare and wellness platform of the Group. During the Interim Period of FY2026, In addition to the specialties services under the brand name of POLYHEALTH and POLYEYE, as well as the dental services under the brand name ofPOLYDENTAL, the Group promoted comprehensive health assessments and tailored treatment plans through the IMPACT health management centre, featuring key diagnosticservices such as FibroScan for liver assessment and DEXA for bone density analysis. New screening services were also introduced for Alzheimer’s disease risk assessment, weight management, and metabolic disorders, highlighting the group’s strategic direction of integrating preventive medicine into routine care. The Day Procedure Centre under the WEHEALTH brand improved its efficiency and utilisation, providing patients with convenient and cost-effective treatment options as an alternative to traditional hospital-based treatment. H2 Pharmacy offered services such as pharmacist medication counselling, “stand-by medications”, prescription dispensing and health screening services, and further enhanced accessibility by offering free consultations via WhatsApp.

Optimised Digital Enablement and Operational Integration
The Group continued to realise operational benefits from its digital capabilities. During the Interim Period of FY2026, the queuing system, including a dedicated priority queue for elderly patients, was in operation at most centres, contributing to smoother patient flow with less waiting time.The omni-channel marketing platform was fully implemented, supporting appointment booking, enquiry management, and ongoing customer communication. The integrated clinic operating system was also implemented in most medical centres, standardising medical documentation filing, coordinating workflows, and improving data interoperability across service points.

Mr. Chan Kin Ping, BBS, JP said “ During the Interim Period of FY2026, we achieved steady growth amidst a complex macro environment. Our core businesses performed well, with consistent and robust development. We remain person-centric, balancing our service quality, operational efficiency, and strategic expansion while deepening digital transformation and public-private partnerships. Looking ahead, we will maintain a cautiously optimistic outlook and create sustainable long-term value for shareholders through strategic network expansion, broadening specialties service scopes, promoting specialised screening services and deepening digital capabilities.”

Business Outlook
Looking ahead to the second half of the FY2026, the Group maintains a positive yet disciplined outlook on the private healthcare sector in Hong Kong. The Group will continue to execute its strategy of demand-driven network expansion, with a key focus on promoting advanced screening and diagnostic services, such as screening for liver health through Fibroscan as well as comprehensive assessments for weight reduction and early-stage Alzheimer’s disease. It is committed to transitioning from a traditional reactive care model to “screening-to-management” approach, providing patients with opportunities for earlier intervention and achieving better long-term health outcomes.

The Healthy Square H2 will continue to remain the focal point for enhancing specialties capacities, with plans to engage further professionals and expand the scope of services. The Dental segment will continue to optimise the synergies following the acquisition of Monarch Dental and focus on the expansion of advanced restorative and aesthetic dental services. At the same time, the Group will further deepen its digital transformation, expand
telemedicine and telehealth offerings, and strengthen the development of its digital healthcare ecosystem to enhance customer convenience and loyalty, creating a more seamless, person-centric digital health journey.

As a vital partner in Hong Kong's public health infrastructure, the Group will continue to deepen public-private collaborations and actively contribute to community health. By balancing strategic network growth with the promotion of specialised screening services and the deepening of its digital capabilities, we will further strengthen our brand and build a sustainable medical and wellness ecosystem. The Group is confident in navigating the complex and challenging economic landscape steadily, continuing to create value for shareholders while steadfastly pursuing its core mission of fostering human health and societal wellness.

- END -

About Human Health Holdings Limited
Human Health, listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 1419), is one of the largest medical groups in Hong Kong. Having been serving the community since 1997, the Group operates more than 60 medical centres, with more than 800 professional team members. With an aim to ”Elevate Your Health Values, Elevate Your Life", Human Health provides comprehensive medical and wellness services including general practice, specialties, dental, eye care, physiotherapy, outreach, rehabilitation and case management, diagnostics and imaging, day procedure and endoscopy, medical aesthetics, Chinese medicine and wellness services as well as the sale of healthcare products and services, being the professional and person-centric care medical and wellness services provider in Hong Kong.

Media Enquiries:
China Times Corporate Advisory Limited
Destiny Cheng
Tel: (852) 6220 0861
Email: pr@ctimes.hk
Fax: (852) 3428 3012